000893091 001__ 893091
000893091 005__ 20210628150955.0
000893091 0247_ $$2doi$$a10.1038/s41531-021-00174-x
000893091 0247_ $$2Handle$$a2128/27915
000893091 0247_ $$2altmetric$$aaltmetric:107290254
000893091 0247_ $$2pmid$$a34103534
000893091 0247_ $$2WOS$$aWOS:000659233200001
000893091 037__ $$aFZJ-2021-02551
000893091 082__ $$a610
000893091 1001_ $$0P:(DE-HGF)0$$aJost, Stefanie T.$$b0$$eCorresponding author
000893091 245__ $$aNon-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
000893091 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2021
000893091 3367_ $$2DRIVER$$aarticle
000893091 3367_ $$2DataCite$$aOutput Types/Journal article
000893091 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1623220602_9210
000893091 3367_ $$2BibTeX$$aARTICLE
000893091 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893091 3367_ $$00$$2EndNote$$aJournal Article
000893091 520__ $$aTo identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.
000893091 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000893091 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893091 7001_ $$0P:(DE-HGF)0$$aVisser-Vandewalle, Veerle$$b1
000893091 7001_ $$0P:(DE-HGF)0$$aRizos, Alexandra$$b2
000893091 7001_ $$00000-0002-5279-2156$$aLoehrer, Philipp A.$$b3
000893091 7001_ $$0P:(DE-HGF)0$$aSilverdale, Monty$$b4
000893091 7001_ $$0P:(DE-HGF)0$$aEvans, Julian$$b5
000893091 7001_ $$0P:(DE-HGF)0$$aSamuel, Michael$$b6
000893091 7001_ $$0P:(DE-HGF)0$$aPetry-Schmelzer, Jan Niklas$$b7
000893091 7001_ $$0P:(DE-HGF)0$$aSauerbier, Anna$$b8
000893091 7001_ $$0P:(DE-HGF)0$$aGronostay, Alexandra$$b9
000893091 7001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael T.$$b10
000893091 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b11
000893091 7001_ $$0P:(DE-HGF)0$$aAshkan, Keyoumars$$b12
000893091 7001_ $$0P:(DE-HGF)0$$aAntonini, Angelo$$b13
000893091 7001_ $$0P:(DE-HGF)0$$aMartinez-Martin, Pablo$$b14
000893091 7001_ $$00000-0003-2815-0505$$aChaudhuri, K. Ray$$b15
000893091 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b16
000893091 7001_ $$00000-0001-8849-4233$$aDafsari, Haidar S.$$b17$$eCorresponding author
000893091 7001_ $$0P:(DE-HGF)0$$aBhidayasiri, Roongroj$$b18
000893091 7001_ $$0P:(DE-HGF)0$$aFalup-Pecurariu, Cristian$$b19
000893091 7001_ $$0P:(DE-HGF)0$$aJeon, Beomseok$$b20
000893091 7001_ $$0P:(DE-HGF)0$$aLeta, Valentina$$b21
000893091 7001_ $$0P:(DE-HGF)0$$aBorghammer, Per$$b22
000893091 7001_ $$0P:(DE-HGF)0$$aOdin, Per$$b23
000893091 7001_ $$0P:(DE-HGF)0$$aSchrag, Anette$$b24
000893091 7001_ $$0P:(DE-HGF)0$$aStorch, Alexander$$b25
000893091 7001_ $$0P:(DE-HGF)0$$aViolante, Mayela Rodriguez$$b26
000893091 7001_ $$0P:(DE-HGF)0$$aWeintraub, Daniel$$b27
000893091 7001_ $$0P:(DE-HGF)0$$aAdler, Charles$$b28
000893091 7001_ $$0P:(DE-HGF)0$$aBarone, Paolo$$b29
000893091 7001_ $$0P:(DE-HGF)0$$aBrooks, David J.$$b30
000893091 7001_ $$0P:(DE-HGF)0$$aBrown, Richard$$b31
000893091 7001_ $$0P:(DE-HGF)0$$aCantillon, Marc$$b32
000893091 7001_ $$0P:(DE-HGF)0$$aCarroll, Camille$$b33
000893091 7001_ $$0P:(DE-HGF)0$$aCoelho, Miguel$$b34
000893091 7001_ $$0P:(DE-HGF)0$$aHenriksen, Tove$$b35
000893091 7001_ $$0P:(DE-HGF)0$$aHu, Michele$$b36
000893091 7001_ $$0P:(DE-HGF)0$$aJenner, Peter$$b37
000893091 7001_ $$0P:(DE-HGF)0$$aKramberger, Milica$$b38
000893091 7001_ $$0P:(DE-HGF)0$$aKumar, Padma$$b39
000893091 7001_ $$0P:(DE-HGF)0$$aKurtis, Mónica$$b40
000893091 7001_ $$0P:(DE-HGF)0$$aLewis, Simon$$b41
000893091 7001_ $$0P:(DE-HGF)0$$aLitvan, Irene$$b42
000893091 7001_ $$0P:(DE-HGF)0$$aLyons, Kelly$$b43
000893091 7001_ $$0P:(DE-HGF)0$$aMartino, Davide$$b44
000893091 7001_ $$0P:(DE-HGF)0$$aMasellis, Mario$$b45
000893091 7001_ $$0P:(DE-HGF)0$$aMochizuki, Hideki$$b46
000893091 7001_ $$0P:(DE-HGF)0$$aMorley, James F.$$b47
000893091 7001_ $$0P:(DE-HGF)0$$aNirenberg, Melissa$$b48
000893091 7001_ $$0P:(DE-HGF)0$$aPagonabarraga, Javier$$b49
000893091 7001_ $$0P:(DE-HGF)0$$aPanicker, Jalesh$$b50
000893091 7001_ $$0P:(DE-HGF)0$$aPavese, Nicola$$b51
000893091 7001_ $$0P:(DE-HGF)0$$aPekkonen, Eero$$b52
000893091 7001_ $$0P:(DE-HGF)0$$aPostuma, Ron$$b53
000893091 7001_ $$0P:(DE-HGF)0$$aRosales, Raymond$$b54
000893091 7001_ $$0P:(DE-HGF)0$$aSchapira, Anthony$$b55
000893091 7001_ $$0P:(DE-HGF)0$$aSimuni, Tanya$$b56
000893091 7001_ $$0P:(DE-HGF)0$$aStocchi, Fabrizio$$b57
000893091 7001_ $$0P:(DE-HGF)0$$aSubramanian, Indu$$b58
000893091 7001_ $$0P:(DE-HGF)0$$aTagliati, Michele$$b59
000893091 7001_ $$0P:(DE-HGF)0$$aTinazzi, Michele$$b60
000893091 7001_ $$0P:(DE-HGF)0$$aToledo, Jon$$b61
000893091 7001_ $$0P:(DE-HGF)0$$aTsuboi, Yoshio$$b62
000893091 7001_ $$0P:(DE-HGF)0$$aWalker, Richard$$b63
000893091 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-021-00174-x$$gVol. 7, no. 1, p. 48$$n1$$p48$$tnpj Parkinson's Disease$$v7$$x2373-8057$$y2021
000893091 8564_ $$uhttps://juser.fz-juelich.de/record/893091/files/Jost_2021_NPJ%20Parkinson%27s%20Disease_Non-motor%20predictors%20of%2036-month....pdf$$yOpenAccess
000893091 909CO $$ooai:juser.fz-juelich.de:893091$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000893091 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b11$$kFZJ
000893091 9130_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000893091 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000893091 9141_ $$y2021
000893091 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-03
000893091 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000893091 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000893091 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-03
000893091 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-03
000893091 920__ $$lyes
000893091 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000893091 980__ $$ajournal
000893091 980__ $$aVDB
000893091 980__ $$aUNRESTRICTED
000893091 980__ $$aI:(DE-Juel1)INM-3-20090406
000893091 9801_ $$aFullTexts